近日，一场引人注目的科技合作备受关注。美国著名的制药巨头礼来公司正式宣布与人工智能领先企业OpenAI达成合作。双方将联手利用生成式AI技术，共同开发新型抗菌药物，以应对日益严重的耐药性病原体问题。
据悉，此次合作旨在将先进的AI技术引入制药领域，有望为行业带来“创新突破”。OpenAI首席运营官Brad Lightcap表示，生成式AI的潜力令人激动，它可能会加速新药研发过程，并帮助解决一些当前难以攻克的医疗难题。
礼来公司的首席信息与数字官Diogo Lau则进一步指出，生成式AI的应用为发现新型抗菌剂以及开发定制化、专业技术以对抗耐药性病原体开辟了新的机遇。这项合作不仅仅是科技与制药领域的结合，更是对全人类健康事业的一次大胆创新。
此次合作标志着人工智能在医药研发领域的应用进入新的阶段。未来，通过利用生成式AI技术，人们可能更快地发现并开发出针对耐药性病原体的新型抗菌药物，从而为全球医疗健康事业作出重要贡献。
这一创新合作的展开，无疑将为整个制药行业带来革命性的变革，我们期待这一合作能早日取得实质性的进展和突破。
英语如下：
News Title: “OpenAI Joins Hands with Giant of the Pharmaceutical Industry: Breakthrough in AI Innovation Supports the Battle Against Bacteria!”
Keywords: OpenAI and Li Lai Cooperation, Generative AI in Developing New Drugs, Combating Drug-resistant Pathogens
News Content:
Recently, a notable technological collaboration has garnered attention. The renowned American pharmaceutical giant, Li Lai Company, officially announced its collaboration with OpenAI, a leading artificial intelligence enterprise. Together, they will leverage generative AI technology to develop new antibacterial drugs to address the increasingly serious issue of drug-resistant pathogens.
It is understood that this collaboration aims to introduce advanced AI technology into the pharmaceutical industry, promising an “innovative breakthrough” for the sector. Brad Lightcap, Chief Operating Officer of OpenAI, stated that the potential of generative AI is exciting and it could accelerate the drug development process, helping to solve some current medical challenges.
Diogo Lau, Chief Information and Digital Officer of Li Lai, further highlighted that the application of generative AI has opened new opportunities for discovering novel antibacterial agents and developing customized, professional technologies to combat drug-resistant pathogens. This collaboration is not just a combination of technology and pharmaceuticals; it is a bold innovation for global health.
This collaboration marks a new stage in the application of artificial intelligence in pharmaceutical research and development. In the future, by utilizing generative AI technology, people may be able to discover and develop new antibacterial drugs against drug-resistant pathogens faster, making significant contributions to global healthcare.
This innovative collaboration will undoubtedly bring revolutionary changes to the entire pharmaceutical industry, and we look forward to seeing substantial progress and breakthroughs from this partnership in the future.
【来源】https://ai-bot.cn/go/?url=aHR0cHM6Ly93d3cuaXRob21lLmNvbS8wLzc3Ny82OTIuaHRt
Views: 1